Abeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at the 13th Annual WORLDSymposium™ 2017 Feb 17, 2017
Abeona Therapeutics Announces Presentations and Posters at the 13th Annual WORLDSymposium™ 2017 Feb 7, 2017
Abeona Therapeutics Enrolls First High Dose Subject in Ongoing Phase 1/2 Gene Therapy Clinical Trial in Sanfilippo Syndrome Type A Feb 1, 2017
Abeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-101 Gene Therapy in Sanfilippo Syndrome Type B Jan 19, 2017
Abeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-201 Gene Therapy Program in Juvenile Batten Disease Jan 3, 2017
Abeona Therapeutics to Present at 2016 Genetic Rx Boston Biotech Conference at Harvard Medical School Dec 6, 2016
Abeona Therapeutics Announces Third Quarter 2016 Financial Results and Recent Clinical Highlights Nov 10, 2016
